Alfadiag’s Post

OPPI has announced a new appointment in its senior leadership, where Mr Bhushan Akshikar will serve as President for a term of 2 years. Akshikar comes with vast experience in senior leadership roles in leading pharmaceutical companies across different geographies. Read More: https://lnkd.in/d2gTxgVq Bhushan Akshikar Organisation of Pharmaceutical Producers of India Anil Matai #indiamedtoday #oppi #healthcare #healthcarenews #healthcareupdates

Mubadala Investment Company, Abu Dhabi’s strategic investment arm, has acquired an 80% stake in Global Medical Supply Chain and Al Ittihad Drug Store from GlobalOne Healthcare Holding, expanding its footprint in healthcare logistics and pharmaceutical distribution. GlobalOne Healthcare Holding will retain a 20% stake in the UAE-based companies, Mubadala said in a statement on Tuesday.

⚕️ 🇮🇹 Italy's Pharmaceutical Legacy: Family-Owned Enterprises Driving Innovation and Global Impact 🇮🇹 ⚕️ 💊 The Italian #pharmaceutical #industry is distinguished by its rich heritage and the enduring presence of family-owned enterprises. Many leading companies trace their origins back over a century, with for example MENARINI Group founded in 1886, Zambon in 1906, Angelini Industries in 1919, Bracco in 1927, Chiesi Group in 1935, and Dompé in 1940. This longstanding tradition of family ownership has fostered a deep commitment to long-term innovation and quality. Italian pharmaceutical companies have successfully navigated the evolving global pharmaceutical landscape, leveraging their heritage to drive advancements in healthcare. 💰 The #Italian pharmaceutical industry, indeed, stands as a pivotal player in Europe, showcasing remarkable growth and innovation. In 2023, Italy's pharmaceutical production value exceeded €52 billion, reinforcing its position among Europe's top producers. 📈 However, when compared to the United States, Europe—including Italy—faces #challenges in pharmaceutical innovation. The U.S. leads in life sciences investments, attracting significant talent and offering competitive salaries, which has resulted in a substantial investment gap between the U.S. and Europe. 🚀 Despite these challenges, Italian pharmaceutical companies are proactively investing in innovation. For instance, Chiesi Group has established Chiesi Ventures, focusing on respiratory, neonatology, and rare diseases. More recently, Angelini Industries launched Angelini Ventures with a record of €300 million to support innovations in the #biotech and life sciences sector. 🎯 These #strategic initiatives highlight Italy's commitment to advancing #healthcare solutions and bridging the innovation gap with global counterparts. The Italian pharma ecosystem continues to evolve, contributing significantly to both the #European and #global healthcare landscapes. 🔬 Their sustained success underscores the significant role that #familyowned enterprises play in the Italian pharmaceutical sector, contributing to its resilience and ongoing contributions to #innovation both in the European and global healthcare.

𝐎𝐧𝐜𝐡𝐨𝐜𝐞𝐫𝐜𝐢𝐚𝐬𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰 𝐚𝐧𝐝 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 The onchocerciasis treatment market is advancing due to increasing global awareness and efforts to eliminate river blindness. Improved healthcare infrastructure, rising government initiatives, and support from global health organizations are driving demand for effective treatments. Ivermectin remains a cornerstone, while research into novel therapies and vaccines is expanding. Partnerships between pharmaceutical companies and non-profit organizations aim to enhance drug accessibility and distribution, fostering progress toward eradicating the disease. 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨@https://lnkd.in/dhjRuEVr 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 Merck Group GSK Johnson & Johnson Novartis Pfizer. AstraZeneca AbbVie. Eisai Co., Ltd. Boehringer Ingelheim TakedaPharmaceutical Nordics AB Alnylam Pharmaceuticals, Amgen. Gilead Sciences Biogen. Teva Pharmaceuticals Ranbaxy Cipla. Dr. Reddy's Laboratories Lupin Torrent Pharmaceuticals Ltd. Apotex Inc. Sandoz Fresenius Medical Care Hikma Pharmaceuticals Viatris. Intas Pharmaceuticals AUROBINDO PHARMA LTD. Mallinckrodt Pharmaceuticals Perrigo Company plc Eli Lilly and Company Shionogi & Co., Ltd Kyowa Kirin Co., Ltd. Sumitomo Pharma Co., Ltd. BioCryst Pharmaceuticals, Inc. Alkem Laboratories Ltd. Glenmark Pharmaceuticals Abbott LEO Pharma Regeneron #OnchocerciasisTreatment #RiverBlindness #GlobalHealth #KeyPlayers #PharmaceuticalInnovation

Gilead Sciences, a leading biopharmaceutical company, has renewed and expanded its partnership with Cigalah Healthcare, a key player in the Saudi healthcare sector, through 2026. This partnership aims to enhance patient care and improve access to medicines across #SaudiArabia. Cigalah Healthcare will secure distribution rights for Gilead's innovative products across various therapeutic areas, leveraging its extensive network to reach more patients. Vitor Papao, General Manager of Gilead Sciences, Middle East, emphasized the importance of this collaboration: "Our ongoing partnership with Cigalah Healthcare is integral to our mission of expanding access to innovative treatments in the Kingdom. This aligns with Vision 2030, as the healthcare sector transforms to meet the needs of society." Yasser Yousuf Naghi, CEO of Cigalah, stated, "For Cigalah, this partnership offers the opportunity to gain valuable expertise in highly specialized and innovative therapy areas, contributing towards the Health Sector Transformation Program." Gilead reaffirms its commitment to becoming an integrated partner in the regional healthcare sector, aligning with ambitious national visions to build a healthier future. #Healthcare #Partnership #GileadSciences #CigalahHealthcare #SaudiArabia #Vision2030 #PatientCare

Roche Pharma appoints a new India head, marking a leadership transition for its operations in the country. Industry shifts and strategic focus in the pharma sector. https://trib.al/lL3azh9

Eli Lilly Shrinks Waistlines as Their Manufacturing Grows to Keep up With Demand Exciting news from Eli Lilly and Company: They recently announced investing an additional $5.3 billion in their Lebanon, Indiana manufacturing plant to meet the surging demand for their popular weight loss and diabetes treatments, Zepbound and Mounjaro. Over the past year, the demand for Zepbound and Mounjaro has significantly exceeded supply, leading to shortages in the U.S. This brings their total investment at the site to $9 billion, marking the largest investment in Eli Lilly’s nearly 150-year history. With operations expected to begin in late 2026, this multi-site campus will leverage the latest technology to deliver their latest medicines. How might this expansion to Eli Lilly’s manufacturing power affect patients and this class of drug in the healthcare industry as a whole? Investors applauded Eli Lilly as the company raised its full-year revenue outlook by $2 billion, driven partly by confidence in increased production of Zepbound, Mounjaro, and other incretin drugs for the remainder of the year. “Now that we’re four months into the year, we have greater visibility into that, into these nodes of capacity and feel more confident,” says Anat Ashkenazi, CFO of Eli Lilly Read more in the article in the comment below. #EliLilly #Zepbound #Mounjaro #HealthcareInnovation #PharmaInvestments #PharmaGrowth #ManufacturingExpansion #DiabetesTreatment #WeightLossSolutions #Pharmaceuticals #Biotech #MedicalAdvancements

Bayer acquires remaining 25% stake in Bayer Zydus Pharma 💊 🤝 💱 In an exciting development, Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited (formerly Cadila Healthcare) have officially concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL). Established on January 28, 2011, as a 50:50 collaboration, this venture focused on the sales and marketing of pharmaceutical products in the dynamic Indian market. Leveraging the complementary strengths of both entities, the joint venture has been instrumental in meeting the burgeoning healthcare demands of India. Zydus's robust domestic marketing strategies, extensive distribution network, and industry connections synergized seamlessly with Bayer's global proficiency in introducing innovative healthcare solutions. BZPPL's impactful contributions span various therapeutic areas, including cardiovascular diseases, diabetes, women’s health, ophthalmology, and oncology, showcasing its versatility and commitment to enhancing patient care. Shweta Rai, Managing Director - India and Country Division Head - South Asia, Bayer's Pharmaceuticals division, expressed her appreciation for Zydus Lifesciences as a valued partner in their shared mission of delivering cutting-edge healthcare solutions to India. As Bayer assumes full ownership of BZPPL, Rai reaffirmed the company's unwavering dedication to maintaining its strong presence and continuing to address the evolving healthcare needs of the Indian populace. #bigpharma #bayer #zydus #pharmaindustry #pharmamanufacturing #pharmaceuticalsales #pharma

THIS IS WHAT Lupin PHARMACEUTICAL LOOKS LIKE! Lupin Pharmaceuticals is committed to global healthcare and innovative solutions. Let's explore what makes them a powerhouse in the pharmaceutical industry. ✅Founder & Shareholders: ↳Desh Bandhu Gupta started the company in 1968. ↳He led it with vision. Today, it has many shareholders and is growing dynamically.  ✅Innovation:  ↳Lupin focuses on research and development. ↳They create new solutions for medical problems. ↳These solutions help people worldwide have better health. ✅Regulatory Bodies: ↳Lupin maintains high quality and safety standards. ↳They work closely with regulatory bodies worldwide to follow strict rules. ↳This helps gain the trust of healthcare workers and patients. ✅Research Institutions:  ↳Lupin collaborates with research institutions worldwide to make progress. ↳They work together to innovate and bring new therapies to the forefront. ✅Global Reach:  ↳Lupin provides healthcare solutions to people all over the world. ↳They are dedicated and caring, serving diverse populations in busy cities and far-off places.  ✅Pricing and Reimbursement:  ↳Lupin's mission is to provide affordable healthcare. ↳They use pricing and reimbursement strategies to make life-saving treatments accessible for everyone, regardless of economic barriers. ✅Research & Development (R&D):  ↳Lupin uses innovation to power its research and development. ↳This helps them create new and better treatments that can solve healthcare problems and help patients worldwide. ✅Manufacturing, Distribution, and Marketing: ↳Lupin has modern manufacturing facilities and a strong distribution network. ↳They offer a variety of drugs, including specialty, over-the-counter, and generic options. ↳Their marketing efforts connect with healthcare professionals and patients. This ensures easy access to their products. ✅Trends and Future Outlook: ↳Healthcare is changing, but Lupin is dedicated to innovation, agility, and excellence. ↳They are ready to adapt to new trends and help shape the future of healthcare worldwide. 🌟P.S. What's your take on the future of healthcare? Please share your thoughts below and let's spark a conversation! Follow Tarannum Shaikh for more amazing content 🤗

𝐁𝐫𝐨𝐧𝐜𝐡𝐢𝐭𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐚𝐧𝐝 𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 The bronchitis market is driven by increasing respiratory diseases, environmental pollution, and a growing geriatric population. The rise in smoking habits and air pollution has led to a surge in chronic respiratory conditions, escalating the demand for effective treatments. Furthermore, advancements in drug therapies and improved healthcare infrastructure contribute to market growth. 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨@https://lnkd.in/dh9Hg-TX 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 GSK, AstraZeneca, Novartis, PFIZER INC., Sanofi, Boehringer Laboratories, LLC, Teva Pharmaceuticals, Merck Group, Mylan, Eli Lilly and Company, Johnson & Johnson, AbbVie, Medtronic Spine & Biologics, UCB, Allergan, Lupin, Boehringer Laboratories, LLC, Chiesi Group, SUN PHARMA, Viatris, Mundipharma, STADA Group, Cipla, Abbott, Zambon, Hikma Pharmaceuticals, Otsuka Pharmaceutical Companies (U.S.), Takeda, Mylan, AstraZeneca, Bayer Sverige, Mallinckrodt Institute of Radiology. #bronchitis #healthcare #respiratorydiseases #marketresearch